Hemogenyx Pharmaceuticals PLC Conversion of Convertible Loan Notes (6219T)
2021年3月26日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 6219T
Hemogenyx Pharmaceuticals PLC
26 March 2021
26 March 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN
THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT
2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Conversion of Convertible Loan Notes and Issue of Ordinary
Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has
received a conversion notice from Mint Capital Advisors Ltd ("Mint
Capital") in respect of GBP900,000 in principal amount of the
Convertible Loan Notes issued by the Company on 3 February
2021.
Pursuant to the conversion, the Company will issue, in
aggregate, 14,285,714 new ordinary shares of GBP0.01 each in the
capital of the Company (the "New Ordinary Shares") at a conversion
price of GBP0.063 per Ordinary Share.
Application will be made to the Financial Conduct Authority and
to the London Stock Exchange for the admission of the New Ordinary
Shares to the standard segment of the Official List and to trading
on the London Stock Exchange's main market for listed securities,
respectively ("Admission"). It is expected that Admission will
occur at 8.00 a.m. on or around 6 April 2021. The New Ordinary
Shares will rank pari passu with the existing issued Ordinary
Shares in the Company.
The Company does not have immediate plans of further drawdowns
from the Convertible Notes Facility.
Total Voting Rights
Following Admission of the New Ordinary Shares, the Company will
have 468,795,217 Ordinary Shares of GBP0.01 each in issue with
voting rights. The Company does not hold any shares in treasury.
This figure may then be used by shareholders in the Company as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Unless defined herein, or the context requires otherwise,
capitalised terms used in this announcement carry the same meaning
as those ascribed to them in the Company's announcement of 18
November 2020.
The person responsible for arranging for the release of this
announcement on behalf of the Company is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
headquarters@hemogenyx.com Peter Redmond, Director
peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew
Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses
as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGLGDXCSDDGBL
(END) Dow Jones Newswires
March 26, 2021 03:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024